BACKGROUND:Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. OBJECTIVE: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. METHODS: Two years of treatment with an ICS, fluticasone propionate (88 microg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. RESULTS: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. CONCLUSIONS: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.
RCT Entities:
BACKGROUND: Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent wheezing at high-risk for development of asthma produces multiple clinical benefits. However, determination of baseline features associated with ICS responsiveness may identify children most likely to benefit from ICS treatment. OBJECTIVE: To determine if demographic and atopic features predict response to ICS in preschool children at high risk for asthma. METHODS: Two years of treatment with an ICS, fluticasone propionate (88 microg twice daily), was compared with matching placebo in a double-masked, randomized, multicenter study of 285 children 2 and 3 years old at high risk for asthma development. Baseline demographic and atopic features were related to clinical outcomes in a post hoc subgroup analysis. RESULTS: Multivariate analysis demonstrated significantly greater improvement with fluticasone than placebo in terms of episode-free days among boys, white subjects, participants with an emergency department (ED) visit or hospitalization within the past year, and those who experienced more symptomatic days at baseline. Children with aeroallergen sensitization experienced greater benefits in terms of oral corticosteroid use, urgent care and ED visits, and use of supplemental controller medications. CONCLUSIONS: More favorable responses to ICS than placebo in high-risk preschool children over a 2-year period were more likely in those with a ED visit or hospitalization for asthma within the past year, children with aeroallergen sensitization, boys, and white subjects.
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: Theresa W Guilbert; Wayne J Morgan; Marzena Krawiec; Robert F Lemanske; Chris Sorkness; Stanley J Szefler; Gary Larsen; Joseph D Spahn; Robert S Zeiger; Gregory Heldt; Robert C Strunk; Leonard B Bacharier; Gordon R Bloomberg; Vernon M Chinchilli; Susan J Boehmer; Elizabeth A Mauger; David T Mauger; Lynn M Taussig; Fernando D Martinez Journal: Control Clin Trials Date: 2004-06
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; David T Mauger; Susan J Boehmer; Stanley J Szefler; Leonard B Bacharier; Robert F Lemanske; Robert C Strunk; David B Allen; Gordon R Bloomberg; Gregory Heldt; Marzena Krawiec; Gary Larsen; Andrew H Liu; Vernon M Chinchilli; Christine A Sorkness; Lynn M Taussig; Fernando D Martinez Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: Gordon R Bloomberg; Kathryn M Trinkaus; Edwin B Fisher; Judith R Musick; Robert C Strunk Journal: Am J Respir Crit Care Med Date: 2003-04-15 Impact factor: 21.405
Authors: Karen McCoy; David M Shade; Charles G Irvin; John G Mastronarde; Nicola A Hanania; Mario Castro; N R Anthonisen Journal: J Allergy Clin Immunol Date: 2006-10-23 Impact factor: 10.793
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; Leonard B Bacharier; Susan J Boehmer; Marzena Krawiec; Gary Larsen; Robert F Lemanske; Andrew Liu; David T Mauger; Chris Sorkness; Stanley J Szefler; Robert C Strunk; Lynn M Taussig; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie Journal: Clin Rev Allergy Immunol Date: 2015-02 Impact factor: 8.667
Authors: Anne M Fitzpatrick; Leonard B Bacharier; Theresa W Guilbert; Daniel J Jackson; Stanley J Szefler; Avraham Beigelman; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Wayne Morgan; Wanda Phipatanakul; Jacqueline A Pongracic; Robert S Zeiger; David T Mauger Journal: J Allergy Clin Immunol Pract Date: 2018-09-26
Authors: Jason E Lang; Anne M Fitzpatrick; David T Mauger; Theresa W Guilbert; Daniel J Jackson; Robert F Lemanske; Fernando D Martinez; Robert C Strunk; Robert S Zeiger; Wanda Phipatanakul; Leonard B Bacharier; Jacqueline A Pongracic; Fernando Holguin; Michael D Cabana; Ronina A Covar; Hengameh H Raissy; Monica Tang; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2017-12-19 Impact factor: 10.793
Authors: Joe K Gerald; Lynn B Gerald; Monica M Vasquez; Wayne J Morgan; Susan J Boehmer; Robert F Lemanske; David T Mauger; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Elizabeth Bade; Ronina A Covar; Theresa W Guilbert; Hengameh Heidarian-Raissy; H William Kelly; Jonathan Malka-Rais; Christine A Sorkness; Lynn M Taussig; Vernon M Chinchilli; Fernando D Martinez Journal: J Allergy Clin Immunol Pract Date: 2015-03-14
Authors: Robert S Zeiger; David Mauger; Leonard B Bacharier; Theresa W Guilbert; Fernando D Martinez; Robert F Lemanske; Robert C Strunk; Ronina Covar; Stanley J Szefler; Susan Boehmer; Daniel J Jackson; Christine A Sorkness; James E Gern; H William Kelly; Noah J Friedman; Michael H Mellon; Michael Schatz; Wayne J Morgan; Vernon M Chinchilli; Hengameh H Raissy; Elizabeth Bade; Jonathan Malka-Rais; Avraham Beigelman; Lynn M Taussig Journal: N Engl J Med Date: 2011-11-24 Impact factor: 91.245